A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial

Nutricion Hospitalaria

Volumn 26, Issue 1, 2011, Pages 228-235

  Mane J ^a,b   Pedrosa, E ^a,b   Loren V ^a,b   Gassull, M A ^a,b   Espadaler, J ^c   Cune J ^c   Audivert, S ^c   Bonachera, M A ^c   Cabre E ^a,b,d  

^a Germans Trias i Pujol Foundation   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c AB BIOTICS SA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Aging; Cytokines; Immune cells; Lactobacillus plantarum; Probiotics

Indexed keywords

BACTERIA (MICROORGANISMS); LACTOBACILLUS PLANTARUM;

CYTOKINE; PROBIOTIC AGENT;

AGED; ARTICLE; BACTERIAL INFECTION; BIOASSAY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMMUNITY; INSTITUTIONALIZATION; LACTOBACILLUS PLANTARUM; LEUKOCYTE COUNT; MALE; MORTALITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY; INSTITUTIONALIZATION; LACTOBACILLUS PLANTARUM; LEUKOCYTE COUNT; MALE; MORTALITY; PILOT PROJECTS; PROBIOTICS; SURVIVAL ANALYSIS;

EID: 79952954901     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2011.26.1.5112     Document Type: Article

References (46)

1. Heczko PB, Strus M, Kochan P. Critical evaluation of probiotic activity of lactic acid bacteria and their effects. J Physiol Pharmacol 2006; 57 (Suppl. 9): 5-12. (Pubitemid 46569845)
2. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001; 33 (Suppl. 2): S17-S25. (Pubitemid 33070120)
3. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109: 678-684. (Pubitemid 34286304)
4. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Doseresponse efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficileassociated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636-1641.
5. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteriafermented milk on ulcerative colitis. J Am Coll Nutr 2002; 22: 56-63.
6. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria- fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141. (Pubitemid 39657947)
7. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10: 126-131.
8. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443.
9. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-9, 1209.
10. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008; 53: 1278-1284. (Pubitemid 351514636)
11. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-2082. (Pubitemid 350275869)
12. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt LJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332.
13. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-1049.
14. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007; CD006475.
15. Kalliomaki M, Antoine JM, Herz U, Rijkers GT, Wells JM, Mercenier A. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics. J Nutr 2010; 140: 713S-721S.
16. De Vrese M., Winkler P, Rautenberg P, Harder T, Noah C, Laue C et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr 2005; 24: 481-491. (Pubitemid 41051901)
17. Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010; 140: 698S-712S.
18. Nova E, Warnberg J, Gomez-Martinez S, Diaz LE, Romeo J, Marcos A. Immunomodulatory effects of probiotics in different stages of life. Br J Nutr 2007; 98 (Suppl. 1): S90-S95. (Pubitemid 47543485)
19. Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr Pharm Des 2009; 15: 1428-1518.
20. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30: 325-333.
21. Agarwal S, Busse PJ. Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol 2010; 104: 183-190.
22. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009; 8: 18-25.
23. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74: 833-839. (Pubitemid 33101806)
24. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001; 20: 149-156. (Pubitemid 32423605)
25. Turchet P, Laurenzano M, Auboiron S, Antoine JM. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study. J Nutr Health Aging 2003; 7: 75-77. (Pubitemid 36506204)
26. Guillemard E, Tondu F, Lacoin F, Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br J Nutr 2010; 103: 58-68.
27. Martinez V, López Q, Gassull MA, Cuñé J, Espadaler J, Cabré E, et al. Strains of Lactobacillus plantarum as probiotics. European Patent 2007; 07121817.6.
28. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Md State Med J 1965; 14: 61-65.
29. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-662. (Pubitemid 32322244)
30. Mazmanian SK, Kasper DL. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 2006; 6: 849-858. (Pubitemid 44631653)
31. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-323.
32. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-118. (Pubitemid 40977944)
33. Walton KL, He J, Kelsall BL, Sartor RB, Fisher NC. Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function. Immunol Lett 2006; 102: 16-24. (Pubitemid 41606035)
34. Ostman S, Rask C, Wold AE, Hultkrantz S, Telemo E. Impaired regulatory T cell function in germ-free mice. Eur J Immunol 2006; 36: 2336-2346. (Pubitemid 44420590)
35. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 2001; 21: 264-271. (Pubitemid 32652598)
36. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32. (Pubitemid 33070205)
37. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006; 176: 705-710. (Pubitemid 43099663)
38. Bulwin GC, Walter S, Schlawinsky M, Heinemann T, Schulze A, Hohne W et al. HLA-DR alpha 2 mediates negative signalling via binding to Tirc7 leading to anti-inflammatory and apoptotic effects in lymphocytes in vitro and in vivo. PLoS One 2008; 3:e1576.
39. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188: 2375-2380. (Pubitemid 29028510)
40. Vintini E, Villena J, Alvarez S, Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 2010; 159: 351-362.
41. Soh SE, Ong DQ, Gerez I, Zhang X, Chollate P, Shek LP, et al. Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination. Vaccine 2010; 28: 2577-2579.
42. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16: 329-343.
43. Castriconi R, Cantoni C, Della CM, Vitale M, Marcenaro E, Conte R et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003; 100: 4120-4125. (Pubitemid 36418167)
44. Veldhoen M, Stockinger B. TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 2006; 27: 358-361. (Pubitemid 44038659)
45. Wan YY, Flavell RA. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 2007; 220: 199-213. (Pubitemid 350064011)
46. Huang MC, Liao JJ, Bonasera S, Longo DL, Goetzl EJ. Nuclear factor-kappaB-dependent reversal of aging-induced alterations in T cell cytokines. FASEB J 2008; 22: 2142-2150. (Pubitemid 351948633)